Ubs Group Ag Lexicon Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 2,095,340 shares of LXRX stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,095,340

Previous 686,117 205.39%

Holding current value

$2.41 Million

Previous $507,000 89.94%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$0.29 - $0.96 $408,674 - $1.35 Million	1,409,223 Added 205.39%	2,095,340 $963,000
Q4 2024 Feb 14, 2025	BUY	$0.65 - $2.08 $354,981 - $1.14 Million	546,125 Added 390.11%	686,117 $507,000
Q3 2024 Nov 14, 2024	SELL	$1.51 - $2.39 $31,892 - $50,479	-21,121 Reduced 13.11%	139,992 $219,000
Q2 2024 Aug 13, 2024	SELL	$1.54 - $2.28 $9,005 - $13,333	-5,848 Reduced 3.5%	161,113 $270,000
Q1 2024 May 13, 2024	SELL	$1.3 - $3.58 $3,451 - $9,504	-2,655 Reduced 1.57%	166,961 $400,000
Q4 2023 Feb 09, 2024	BUY	$1.0 - $1.53 $44,254 - $67,708	44,254 Added 35.3%	169,616 $259,000
Q3 2023 Nov 09, 2023	BUY	$1.06 - $2.33 $29,466 - $64,771	27,799 Added 28.49%	125,362 $136,000
Q2 2023 Aug 11, 2023	SELL	$2.15 - $3.49 $88,500 - $143,658	-41,163 Reduced 29.67%	97,563 $223,000
Q1 2023 May 12, 2023	SELL	$1.99 - $2.68 $41,973 - $56,526	-21,092 Reduced 13.2%	138,726 $337,000
Q4 2022 Feb 08, 2023	BUY	$1.8 - $2.56 $119,037 - $169,297	66,132 Added 70.59%	159,818 $305,000
Q3 2022 Nov 10, 2022	SELL	$1.94 - $3.43 $229,825 - $406,341	-118,467 Reduced 55.84%	93,686 $225,000
Q2 2022 Aug 10, 2022	BUY	$1.31 - $2.69 $113 - $234	87 Added 0.04%	212,153 $395,000
Q1 2022 May 16, 2022	BUY	$1.95 - $3.89 $226,328 - $451,496	116,066 Added 120.9%	212,066 $443,000
Q4 2021 Feb 14, 2022	BUY	$3.81 - $6.16 $350,619 - $566,880	92,026 Added 2315.7%	96,000 $378,000
Q3 2021 Nov 15, 2021	BUY	$3.38 - $5.35 $6,702 - $10,609	1,983 Added 99.6%	3,974 $19,000
Q2 2021 Aug 13, 2021	SELL	$4.12 - $5.87 $48,026 - $68,426	-11,657 Reduced 85.41%	1,991 $9,000
Q1 2021 May 12, 2021	BUY	$3.45 - $9.09 $3 - $9	1 Added 0.01%	13,648 $80,000
Q4 2020 Feb 11, 2021	BUY	$1.05 - $3.67 $11,262 - $39,364	10,726 Added 367.2%	13,647 $46,000
Q3 2020 Nov 12, 2020	SELL	$1.44 - $2.1 $34,516 - $50,337	-23,970 Reduced 89.14%	2,921 $4,000
Q2 2020 Jul 31, 2020	BUY	$1.75 - $2.3 $18,228 - $23,956	10,416 Added 63.22%	26,891 $54,000
Q1 2020 May 01, 2020	SELL	$1.8 - $4.28 $57,551 - $136,844	-31,973 Reduced 65.99%	16,475 $32,000
Q4 2019 Feb 14, 2020	BUY	$3.16 - $5.15 $77,009 - $125,505	24,370 Added 101.21%	48,448 $201,000
Q3 2019 Nov 14, 2019	BUY	$1.2 - $6.66 $19,755 - $109,643	16,463 Added 216.19%	24,078 $73,000
Q2 2019 Aug 14, 2019	BUY	$5.35 - $7.11 $12,786 - $16,992	2,390 Added 45.74%	7,615 $48,000
Q1 2019 May 14, 2019	SELL	$4.36 - $7.94 $752,801 - $1.37 Million	-172,661 Reduced 97.06%	5,225 $29,000
Q4 2018 Feb 14, 2019	BUY	$6.15 - $10.51 $91,155 - $155,779	14,822 Added 9.09%	177,886 $1.18 Million
Q3 2018 Nov 14, 2018	BUY	$10.32 - $13.06 $416,979 - $527,689	40,405 Added 32.94%	163,064 $1.74 Million
Q2 2018 Aug 14, 2018	SELL	$7.8 - $13.69 $750,859 - $1.32 Million	-96,264 Reduced 43.97%	122,659 $1.47 Million
Q1 2018 May 15, 2018	BUY	$7.86 - $11.39 $836,241 - $1.21 Million	106,392 Added 94.54%	218,923 $1.88 Million
Q4 2017 Feb 14, 2018	SELL	$8.77 - $12.28 $404,428 - $566,292	-46,115 Reduced 29.07%	112,531 $1.11 Million
Q3 2017 Nov 14, 2017	BUY	$12.17 - $16.3 $308,266 - $412,879	25,330 Added 19.0%	158,646 $1.95 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,446 Added 1.87%	133,316 $2.19 Million
Q1 2017 Nov 14, 2017	BUY	N/A	130,870	130,870 $1.88 Million

Others Institutions Holding LXRX

# of Institutions

135

Shares Held

199M

Call Options Held

310K

Put Options Held

77.3K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $217M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account